There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cybin (CYBN – Research Report), ADMA Biologics (ADMA – Research Report) and Halozyme (HALO – Research Report) with bullish sentiments.
Cybin (CYBN)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Cybin today and set a price target of $5.00. The company’s shares closed last Thursday at $0.45.
According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of
Cybin has an analyst consensus of Strong Buy, with a price target consensus of $4.25.
See the top stocks recommended by analysts >>
ADMA Biologics (ADMA)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ADMA Biologics, with a price target of $5.00. The company’s shares closed last Thursday at $3.81.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
ADMA Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00, a 57.9% upside from current levels. In a report issued on November 9, Mizuho Securities also reiterated a Buy rating on the stock with a $7.00 price target.
Halozyme (HALO)
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme, with a price target of $61.00. The company’s shares closed last Thursday at $39.52.
According to TipRanks.com, Kapoor has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Halozyme with a $51.50 average price target, representing a 31.3% upside. In a report issued on November 7, Piper Sandler also maintained a Buy rating on the stock with a $46.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYBN:
- Cybin reports Q2 net income (C$11.9M) vs (C$10M) last year
- Cybin, Inc. (CYBN) Q2 Earnings Cheat Sheet
- Cybin’s depressive disorder candidate meets Phase 2 efficacy endpoint
- Cybin reports CYB003 demonstrated reduction in symptoms of depression
- Cybin announces grant of two US patents protecting deuterated DMT program
